Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 260
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Ixabepilone, 32 mg/m^2 intervention 2: Paclitaxel, 200 mg/m^2 intervention 3: Carboplatin (area under the concentration curve [AUC] 6)
Intervention descriptions: intervention 1: Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2 intervention 2: IV solutions, paclitaxel, 200 mg/m\^2 intervention 3: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles

Protocol document: